SEC EDGAROCT 161 min read$MDT

Marinaro Michael sold $1.0M of MDT

Marinaro Michael (EVP, Pres MedSurg and Americas) sold 10,420 shares of Medtronic plc (MDT) at $96.00 ($1.00M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Marinaro Michael

Published Oct 16, 2026, 10:02 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 16, 2026, 10:06 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$MDT

Bearish

high confidence

Mentioned

$MDT

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$MDTBearishLow

Why it matters

The disclosed sale adds a data point for traders monitoring insider activity; historically, such sales can precede short‑term price dips.

Market read

While the transaction is modest, it provides fresh insider information that may influence short‑term trading decisions.

What to watch

Potential upcoming earnings or product announcements could offset any negative sentiment from the sale.

Relevance 5/10Novelty 3/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; this filing reports a $1M sale by a senior Medtronic executive.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MDTBearishHigh confidence

Context

EVP and Pres MedSurg Michael Marinaro sold 10,420 Medtronic shares for $1.0M via a Form 4 filing.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

C‑suite insider sales are watched by traders; a $1M sale is modest but may trigger short‑term downside bias.

Market effects

Sector

Minimal impact on the broader medical device sector; similar insider sales are routine.

Regional

Limited to U.S. investors tracking Medtronic; no broader regional effect.

Global

Low global relevance; Medtronic is a large cap but the transaction size is small.

Counterpoint

What could challenge this read

The sale could be unrelated to company outlook; investors might view it as routine portfolio rebalancing.

Key entities

company
Medtronic plc
Global medical device manufacturer (ticker MDT).
person
Marinaro Michael
Executive Vice President, President MedSurg and Americas at Medtronic.

Read at source ← All news

OCT 23

$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

hcplive.com2 min

OCT 23

$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

finance.yahoo.com2 min

OCT 22

$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min

OCT 22

$MDTMedAI 8/10

Medtronic Reports Positive Real-World Data For Cardiac Ablation Systems

Medtronic (MDT) presented positive real-world data for its cardiac ablation systems at the APHRS 2026 meeting. The Sphere-9 catheter and PulseSelect PFA system showed low complication rates and high success rates in treating heart rhythm disorders. MDT stock closed at $93.03, up 0.25% in pre-market trading.

rttnews.com2 min

OCT 20

MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

medicaldevice-network.com2 min

OCT 19

$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.